SUZ12在舌鳞癌中的表达及临床意义

›› 2018, Vol. 38 ›› Issue (6): 499-502.

SUZ12在舌鳞癌中的表达及临床意义

胡慧君¹,李中武²,王琼¹,吴亚平¹,杨建荣³

1. 南京医科大学附属口腔医院
2. 江苏省口腔医院
3. 南京医科大学口腔医学研究所，南京医科大学口腔医院

收稿日期:2017-11-27 修回日期:2018-01-04 出版日期:2018-06-28 发布日期:2018-07-05
通讯作者: 杨建荣 E-mail:jrjskq@163.com
基金资助:
江苏省高校优势学科;江苏省自然科学基金

Expression and clinical significance of SUZ12 in tongue squamous cell carcinoma

Received:2017-11-27 Revised:2018-01-04 Online:2018-06-28 Published:2018-07-05

摘要/Abstract

摘要： 目的　研究多梳蛋白家族成员SUZ12在舌鳞状细胞癌（以下简称舌鳞癌）中的表达及其与多种临床病理参数之间的关系，探讨其在舌鳞癌预后判断中的意义。方法采用免疫组织化学染色半定量的方法检测72例术前未接受放、化疗或其他特殊治疗的原发性舌鳞癌患者标本及15例正常舌黏膜中SUZ12的表达情况，结合临床资料，对其与舌鳞癌临床病理特征和预后的相关性进行统计学分析。结果 SUZ12在舌鳞癌组中的表达明显高于正常舌黏膜。舌鳞癌组织中SUZ12的表达与患者年龄、性别、抽烟、饮酒、肿瘤大小、病理分级、临床分期之间在统计学上无显著性差异，与颈部淋巴结转移（P=0.0325）、总体生存率（P=0.0225）及无瘤生存率（P=0.0179）相关。结论 SUZ12在舌鳞癌组织中过表达与颈淋巴结转移及低生存率相关，可能作为舌鳞癌诊断和预后判断的指标。

关键词: SUZ12, 舌鳞癌, 免疫组织化学

Abstract: Objective　 To investigate the expression of SUZ12 in tongue squamous cell carcinoma (TSCC) and its correlation with clinical pathological parameters, to investigate its significance in TSCC treatment and tumor prognosis. Methods Immunohistochemistry was used to examine the expression of SUZ12 in samples from 72 patients with TSCC and 15 normal tongue mucosa. The associations between SUZ12 and multiple clinicopathological parameters and prognosis were analyzed. Results The expression of SUZ12 was significantly higher in TSCC than in normal tongue mucosa. There were no statistically significant differences between the expression levels of SUZ12 and age, sex, smoking, alcohol use, tumor size, pathological grade and clinical stage (P>0.05). However, its over-expression was correlated with cervical node metastasis(P=0.0325), reduced overall survival rate (P=0.0225) and disease-free survival rate(P=0.0179). Conclusions Our data reveal that aberrant SUZ12 over-expression is associated with cervical nodes metastasis and reduced survival rate in TSCC, suggesting that SUZ12 might serve as a novel biomarker with diagnostic and prognostic significance.

Key words: SUZ12, tongue squamous cell carcinoma, immunohistochemistry

中图分类号:

R739.86

胡慧君李中武王琼吴亚平杨建荣. SUZ12在舌鳞癌中的表达及临床意义[J]. , 2018, 38(6): 499-502.

参考文献

[1] CHI A C, DAY T A, NEVILLE B W. Oral cavity and oropharyngeal squamous cell carcinoma--an update [J]. CA Cancer J Clin, 2015, 65(5): 401-21.
[2] SCULLY C, BAGAN J. Oral squamous cell carcinoma overview [J]. Oral Oncol, 2009, 45(4-5): 301-8.
[3] BELLO I O, SOINI Y, SALO T. Prognostic evaluation of oral tongue cancer: means, markers and perspectives (II) [J]. Oral Oncol, 2010, 46(9): 636-43.
[4] SUVA M L, RIGGI N, BERNSTEIN B E. Epigenetic reprogramming in cancer [J]. Science, 2013, 339(6127): 1567-70.
[5] SIMON J A, KINGSTON R E. Mechanisms of polycomb gene silencing: knowns and unknowns [J]. Nat Rev Mol Cell Biol, 2009, 10(10): 697-708.
[6] MARGUERON R, REINBERG D. The Polycomb complex PRC2 and its mark in life [J]. Nature, 2011, 469(7330): 343-9.
[7] LI Z, WANG Y, QIU J, et al. The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer [J]. Oncotarget, 2013, 4(12): 2532-49.
[8] LI Z, WANG Y, YUAN C, et al. Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer [J]. Lab Invest, 2014, 94(12): 1431-45.
[9] HE Q, LIU Z, ZHAO T, et al. Bmi1 drives stem-like properties and is associated with migration, invasion, and poor prognosis in tongue squamous cell carcinoma [J]. Int J Biol Sci, 2015, 11(1): 1-10.
[10] CAO R, ZHANG Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex [J]. Mol Cell, 2004, 15(1): 57-67.
[11] LI H, CAI Q, WU H, et al. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK [J]. Mol Cancer Res, 2012, 10(11): 1462-72.
[12] LIU C, SHI X, WANG L, et al. SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis [J]. Tumour Biol, 2014, 35(6): 6073-82.
[13] LIU Y L, GAO X, JIANG Y, et al. Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer [J]. J Cancer Res Clin Oncol, 2015, 141(4): 661-9.
[14] PASINI D, DI CROCE L. Emerging roles for Polycomb proteins in cancer [J]. Curr Opin Genet Dev, 2016, 36(50-8.
[15] SAUVAGEAU M, SAUVAGEAU G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer [J]. Cell Stem Cell, 2010, 7(3): 299-313.
[16] LEE S R, ROH Y G, KIM S K, et al. Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer [J]. Clin Cancer Res, 2015, 21(23): 5391-403.
[17] GONZALEZ-RAMIREZ I, SOTO-REYES E, SANCHEZ-PEREZ Y, et al. Histones and long non-coding RNAs: the new insights of epigenetic deregulation involved in oral cancer [J]. Oral Oncol, 2014, 50(8): 691-5.
[18] JITHESH P V, RISK J M, SCHACHE A G, et al. The epigenetic landscape of oral squamous cell carcinoma [J]. Br J Cancer, 2013, 108(2): 370-9.
[19] HERRANZ N, PASINI D, DIAZ V M, et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor [J]. Mol Cell Biol, 2008, 28(15): 4772-81.
[20] XIA R, JIN F Y, LU K, et al. SUZ12 promotes gastric cancer cell proliferation and metastasis by regulating KLF2 and E-cadherin [J]. Tumour Biol, 2015, 36(7): 5341-51.
[21] ILIOPOULOS D, LINDAHL-ALLEN M, POLYTARCHOU C, et al. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells [J]. Mol Cell, 2010, 39(5): 761-72.
[22] CREA F, HURT E M, MATHEWS L A, et al. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer [J]. Mol Cancer, 2011, 10(40.